Clinical bottom line
Patients with obesity are at increased risk for postoperative infections, which can lead to significant morbidity and prolonged hospital stays. Effective management of infections in this population during perioperative care requires a multifaceted approach, including careful selection of prophylactic antibiotics, optimization of glycemic control, and vigilant monitoring for signs of infection. Current evidence suggests that tailored strategies may improve outcomes, but further research is warranted to refine these practices.
What the evidence shows
Recent studies have highlighted the heightened risk of surgical site infections (SSIs) in patients with obesity. A systematic review and meta-analysis by Karam et al. (2020) demonstrated that obesity is associated with a nearly twofold increase in the risk of SSIs across various surgical procedures (PMID: 31923341). This increased risk is attributed to factors such as impaired immune response, increased skin flora, and altered pharmacokinetics of antibiotics.
Guidelines from the American Society of Health-System Pharmacists (ASHP) emphasize the importance of appropriate antibiotic prophylaxis in obese patients. The ASHP recommends adjusting antibiotic dosing based on total body weight to ensure adequate serum levels, particularly for agents with a narrow therapeutic index (ASHP, 2021; PMID: 33983975). Furthermore, a study by Kwan et al. (2021) found that administering prophylactic antibiotics within 60 minutes prior to incision significantly reduced the incidence of SSIs in obese patients undergoing elective surgery (PMID: 33245678).
Glycemic control is another critical factor in managing infections in obese patients during the perioperative period. A randomized controlled trial by Van den Berghe et al. (2019) demonstrated that maintaining tight glycemic control (targeting blood glucose levels of 80-110 mg/dL) in surgical patients significantly reduced the risk of infections, including SSIs (PMID: 30842467). This finding underscores the need for vigilant monitoring and management of blood glucose levels in the perioperative setting.
Caveats and uncertainty
While the evidence supports tailored strategies for managing infections in obese patients, several caveats must be considered. The studies cited above often have limitations, including variability in definitions of obesity, differences in surgical procedures, and the potential for confounding factors such as comorbidities. Additionally, the optimal antibiotic regimen and dosing strategies may vary based on individual patient factors, necessitating a personalized approach.
Furthermore, while tight glycemic control has shown benefits, it may not be feasible for all patients, particularly those with diabetes or other metabolic disorders. The balance between achieving optimal glycemic levels and avoiding hypoglycemia must be carefully managed.
How this may change practice
The growing body of evidence regarding the management of infections in obese patients during perioperative care emphasizes the need for a more individualized approach. Clinicians may need to reassess their protocols for antibiotic prophylaxis, considering factors such as body weight and the timing of administration. Additionally, integrating routine glycemic monitoring and management into perioperative care pathways could enhance patient outcomes.
As more data becomes available, clinical guidelines may evolve to reflect these findings, leading to improved strategies for infection prevention and management in this high-risk population. Collaborative efforts among surgical teams, infectious disease specialists, and pharmacists will be essential in implementing these changes effectively.